Monday, 1 April 2013

Update on ACT's clinical trials for macular degeneration

Advanced Cell Technology (ACT) just announced the treatment of the patients in the third patient cohort, in each of the two U.S stem cell clinical trials, on people suffering from various types of macular degeneration.

Each of the treated patients received, via injection, about 150,000 retinal pigment epithelial cells, derived from human embryonic stem cells, while the three patients belonging to the second cohort received about 100,000 cells. According to the press release, the first patient, suffering from dry age-related macular degeneration, was treated on Tuesday, March 26 in an undisclosed location and the second, suffering from Stargardt’s Macular Dystrophy, on Wednesday, March 27 at the University of Miami Miller School of Medicine. ACT says that the both of them are recovering "uneventfully".

Robert Lanza, Chief Scientific Officer of ACT, said that as of now 20 patients have received stem cell therapy, adding that they are very eager to treat "the third patient cohort in our European trial".

Video of Robert Lanza

Gary Rabin, ACT's chairman and CEO of ACT said:

“We are very pleased to have commenced with treatment of the third patient cohort in both of our U.S. clinical trials, We are eagerly anticipating completing this cohort and moving on to the fourth one. We are also looking forward to initiating treatment of patients with better vision in cohort 2a, for which we are currently reviewing and qualifying patients.”

Interview with Gary Rabin

You can access the official press release here

Related Posts

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !